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Abstract
Introduction: The multiple biological responses to estrogens are mainly mediated by the classical estrogen
receptors ERa and ERb, which act as ligand-activated transcription factors. ERa exerts a main role in the
development of breast cancer; therefore, the ER antagonist tamoxifen has been widely used although its
effectiveness is limited by de novo and acquired resistance. Recently, GPR30/GPER, a member of the seven-
transmembrane G protein-coupled receptor family, has been implicated in mediating the effects of estrogens in
various normal and cancer cells. In particular, GPER triggered gene expression and proliferative responses induced
by estrogens and even ER antagonists in hormone-sensitive tumor cells. Likewise, additional ER ligands showed the
ability to bind to GPER eliciting promiscuous and, in some cases, opposite actions through the two receptors. We
synthesized a novel compound (ethyl 3-[5-(2-ethoxycarbonyl-1-methylvinyloxy)-1-methyl-1H-indol-3-yl]but-2-
enoate), referred to as MIBE, and investigated its properties elicited through ERa and GPER in breast cancer cells.
Methods: Molecular modeling, binding experiments and functional assays were performed in order to evaluate the
biological action exerted by MIBE through ERa and GPER in MCF7 and SkBr3 breast cancer cells.
Results: MIBE displayed the ability to act as an antagonist ligand for ERa and GPER as it elicited inhibitory effects
on gene transcription and growth effects by binding to both receptors in breast cancer cells. Moreover, GPER was
required for epidermal growth factor receptor (EGFR) and ERK activation by EGF as ascertained by using MIBE and
performing gene silencing experiments.
Conclusions: Our findings provide novel insights on the functional cross-talk between GPER and EGFR signaling.
Furthermore, the exclusive antagonistic activity exerted by MIBE on ERa and GPER could represent an innovative
pharmacological approach targeting breast carcinomas which express one or both receptors at the beginning and/
or during tumor progression. Hence, the simultaneous inhibition of both ERa and GPER may guarantee major
therapeutic benefits in respect to the use of a selective estrogen receptor antagonist.
Introduction
Estrogens regulate many aspects of human physiology
and influence diverse pathological processes, including
the development of hormone-dependent tumors [1].
The biological actions of estrogens are mainly mediated
by the estrogen receptor (ER)a and ERb, which belong
to the nuclear receptor superfamily [1]. Acting as
ligand-activated transcription factors, ERs regulate gene
expression by binding to responsive elements (ERE)
located within the promoter region of estrogen target
genes [1]. In addition, gene regulation can occur in
response to estrogens through plasma membrane recep-
tors, such as growth factor receptors or G protein-
coupled receptors, and by protein kinase signaling cas-
cades [2].
Prolonged exposure to estrogens represents a major
risk factor for the progression of breast cancer [3],
which expresses elevated levels of ERa in approximately
70% of cases [4]. Consequently, ERa antagonists like
tamoxifen and raloxifene are currently used as frontline
pharmacological interventions in ERa-positive breast
cancer in order to inhibit the mitogenic stimulation of
estrogens [5]. Although there is general concordance
between ERa expression and responsiveness to ER-
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targeted agents, as indicated by a greater five-year dis-
ease-free survival for ERa-positive patients receiving
tamoxifen, one in four patients does not respond to
treatment from the onset and in most patients tamoxi-
fen produces agonist effects after a few years [6].
In order to further characterize the molecular
mechanisms involved in the action of estrogens, recent
studies have demonstrated that the G protein-coupled
receptor, named GPR30/GPER, mediates rapid biological
responses to estrogens in diverse normal, as well as
transformed, cell types [7]. The potential role of GPER
in cancer was supported by numerous investigations
performed in different tumor cells, including breast
[8-10], endometrial [11], ovarian [12], thyroid [13], pros-
tate [14] and testicular germ cells [15]. In accordance
with these findings, GPER has been associated with
aggressive features of breast cancer [16], high-grade
endometrial tumors [17] and poor prognosis in ovarian
cancer [18]. Since its identification to date, the transduc-
tion signaling and gene expression profile triggered by
GPER have been extensively characterized. The early
discovery [8] of a transmembrane receptor able to med-
iate estrogen responsiveness in ER-negative breast can-
cer cells was then confirmed by several reports by which
GPER was considered as a genuine ER [10,19]. Indeed, a
whole series of intracellular events, such as the rapid
phosphorylation of mitogen-activated protein kinases
(MAPK) ERK1/2, the activation of PI3-kinase (PI3K)
and phospholipase C (PLC), the increase in cAMP con-
centrations and the intracellular calcium mobilization,
was shown to follow GPER activation by both estrogens
and anti-estrogens [20]. In particular, it was demon-
strated that GPER-dependent ERK activation occurs via
the transactivation of the epidermal growth factor recep-
tor (EGFR) through matrix metalloproteinase activity
and integrin a5b1, which trigger the extracellular release
of heparan-bound epidermal growth factor (HB-EGF)
[8,21]. Interestingly, a physical and functional cross-talk
between GPER and EGFR contributes to the intricate
signaling network involved in the stimulation of hor-
mone-sensitive tumors [22,23].
The rapid responses to estrogenic signals mediated by
GPER regulate a typical gene signature, as revealed in
previous studies, including a microarray analysis [7,24].
Of note, GPER target genes were shown to contribute
to the proliferation and migration in diverse cancer cell
types [9,11-13,22,24,25] as well as in cancer associated
fibroblasts (CAFs) [26].
GPER exhibits many of the expected characteristics of
an estrogen receptor, including the capability to bind to
estrogens, phyto- and xenoestrogens and even the ER
antagonists 4-hydroxytamoxifen (OHT) and fulvestrant
(ICI 182 780) [10,19,27,28]. Surprisingly, unlike the
antagonistic properties displayed by these anti-estrogens
with respect to the classical ERs, both compounds act as
GPER agonists [8,11,19,24]. Conversely, the well known
ER agonist estriol exerts inhibitory effects on GPER-
mediated signaling [28], confirming the potential oppo-
site functions elicited by estrogenic/anti-estrogenic
agents through each type of estrogen receptor. In addi-
tion to the selective GPER agonist G-1 [29], GPER
ligands showing antagonistic properties have been iden-
tified [30,31]. Recently, a GPER antagonist showed at
high concentrations limited binding properties and sti-
mulatory activity on ER-mediated transcription [30].
The use of these compounds has greatly advanced our
understanding of the role of GPER in numerous biologi-
cal systems as well as in cancer.
On the basis of the aforementioned findings, GPER
may be considered as an additional therapeutic target in
estrogen-sensitive tumors, such as breast cancer. In this
regard, the opposite functional activity elicited by anti-
estrogens through the classical ERs and GPER as stated
above, could represent a therapeutic concern toward the
pharmacological inhibition of all types of estrogen
receptor.
We discovered a novel compound, ethyl 3-[5-(2-ethox-
ycarbonyl-1-methylvinyloxy)-1-methyl-1H-indol-3-yl]
but-2-enoate (referred to as MIBE) (Figure 1), which
displays the unique property to bind to and inhibit
GPER- and ERa-mediated signaling in breast cancer
cells. The antagonistic action exerted by MIBE on both
estrogen receptor types could represent a novel, promis-
ing tool for a more comprehensive pharmacological
approach to estrogen-dependent tumors such as breast
cancer.
Materials and methods
Molecular modelling and docking simulations
For docking simulations we used as targets the crystal-
lographic coordinates of ERa in complex with E2
(closed-conformation) as well as with OHT (open con-
formation) and a GPER molecular model built by
homology as described elsewhere (PDB code 1G50;
PDB code 3ERT) [28,32,33]. Docking studies were per-
formed by GOLD 5.0.1 (the Cambridge Crystallo-
graphic Data Center, UK), a program using a genetic
algorithm useful to investigate the full range of ligand
conformational flexibility and a partial protein side
chain flexibility. As active sites of ERa, we identified
those atoms that are within 20 Å distance from each
atom of the ligand experimental position. Regarding
GPER, we identified the O atom of Phe 208 as the pro-
tein active site centre on the basis of our previous
docking simulations [28]. In this case, the active site
atoms were considered those located within 20 Å from
the centre. For each structure, 10 docking solutions
were generated allowing an early termination of the
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process, if the respective RMSDs of the three highest
ranked docking solutions were within 1.5 Å of each
other. The default GOLD settings were used for run-
ning the simulations. ERa protein side chains Met342,
Glu353, Trp383, Met388, Arg394, Phe404, His524 and
Leu525 were considered as flexible, while in the GPER
model the residues Tyr123, Gln138, Phe206, Phe208,
Glu275, Phe278 and His282 were defined flexible side
chains allowing their free rotation. The molecular
structures of the ligands screened in silico were built
and energy minimized with the programs Insight II
and Discover3 (Biosym/MSI, San Diego, CA, USA). All
the figures were drawn with the program Chimera
(UCSF, San Francisco, CA, USA) [34].
Chemistry
5-Hydroxy-1-methylindole was allowed to react with
an excess of ethyl acetoacetate using Indium(III) chlor-
ide as a catalyst. The derivative ethyl 3-[5-(2-ethoxy-
carbonyl-1-methylvinyloxy)-1-methyl-1H-indol-3-yl]
but-2-enoate (MIBE) was obtained in good yield
[35,36]. Melting points were determined on a Kofler
melting point apparatus. IR spectra were taken with a
Perkin Elmer BX FT-IR (Corporate Headquarters, Wal-
tham, Massachusetts, USA). Mass spectra were taken
on a JEOL JMS GCMate spectrometer at ionising
potential of 70 eV (EI). 1H-NMR (400 MHz) was
recorded on a JEOL Lambda 400 Spectrometer (JEOL
Ltd., Tokyo, Japan). Chemical shifts are expressed in
parts per million downfield from tetramethylsilane as
an internal standard. Thin layer chromatography
(TLC) was performed on silica gel 60F-264 (Merck,
Frankfurt, Germany). Commercial reagents were pur-
chased from Aldrich Chemical (Milan, Italy), Acros
Organics (Carlo Erba Reagenti S.p.A., Rodano, Milan,
Italy) and Alfa Aesar (Karlsruhe, Germany). Unless
otherwise stated, all commercial reagents were used
without further purification.
Procedure for the preparation of MIBE was as follows.
Indium (III) chloride (10 mol%) was added under nitro-
gen to a mixture of 5-hydroxy-1-methyl-1H-indole and
ethyl acetoacetate. The reaction mixture was heated
under reflux for two hours, and then it was left to cool to
room temperature. Ice water was added and then the
reaction mixture was extracted by ethyl acetate. The
organic layers were collected and washed with brine,
dried over MgSO4 and evaporated under reduced pres-
sure. The solid residue was washed with Et2O, to give the
pure compound MIBE a pink solid, yield of 65%, mp =
180°C; IR (KBr): 3412, 2984, 1705, 1622, 1473, 1373,
1168, 1088, 1027, 805 cm-1. 1H-NMR (d6-DMSO) δ 8.94
(s, 1H, Ar); 7.32 (d, 1H, Ar, J7,6 = 8.8 Hz); 6.87 (s, 1H,
Ar); 7.32 (d, 1H, Ar, J6,7 = 8.8 Hz); 6.04-6.01 (m, 2H, C =
CH); 4.11-4.09 (q, 2H, CH2); 3.90-3.88 (q, 2H, CH2); 3.76
(s, 3H, NCH3); 1.42 (s, 6H, C-CH3); 1.24-1.20 (t, 3H,
CH3); 0.95-0.92 (t, 3H, CH3). MS (EI) m/z: 371 (M
+, 14).
Reagents
17b-estradiol (E2), 4-hydroxytamoxifen (OHT) and 5a-
dihydrotestosterone (DHT) were purchased from Sigma-
Aldrich (Milan, Italy). G-1 (1-[4-(-6-bromobenzol [1,3]
diodo-5-yl)-3a,4,5,9b-tetrahidro3H5 cyclopenta[c]quino-
lin-8yl]-ethanone) was bought from Calbiochem (Merck
KGaA, Frankfurt, Germany). All compounds were solu-
bilized in ethanol, except G-1 and MIBE which were
dissolved in dimethyl sulfoxide (DMSO).
Cell culture
MCF7 breast cancer cells and human embryonal kidney
Hek293 cells were maintained in DMEM with phenol
red supplemented with 10% FBS. SkBr3 breast cancer
cells were maintained in RPMI 1640 without phenol red
supplemented with 10% FBS. All cell lines to be pro-
cessed for immunoblot and RT-PCR assays were
switched to medium without serum and phenol red the
day before treatments.
Figure 1 Chemical structures of compounds used. 17beta-estradiol (E2), 4-hydroxytamoxifen (OHT), G-1 and ethyl 3-[5-(2-ethoxycarbonyl-1-
methylvinyloxy)-1-methyl-1H-indol-3-yl]but-2-enoate (MIBE).
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The experiments performed in this study do not
require Institute Ethics Board approval, because only
commercially available cell lines were used.
Plasmids
Firefly luciferase reporter plasmids used were ERE-luc
for ERa [37], ARE-luc for the Androgen Receptor (AR)
[38] and GK1 [37] for the Gal4 fusion proteins Gal-ERa
and Gal-ERb, which were expressed from plasmids
GAL93.ER(G) and GAL93.ERb, respectively, as pre-
viously described [37]. The full length AR expression
plasmid (AR) was previously described [39]. As the
internal transfection control, we co-transfected the plas-
mid pRL-TK (Promega, Milan, Italy) that expresses
Renilla Luciferase. Short hairpin RNA construct against
human GPER (shGPR30/shGPER) and the unrelated
shRNA control construct were previously described [22].
Transfection, Luciferase assays and gene silencing
experiments
Cells were plated into 24-well plates with 500 μl of reg-
ular growth medium/well the day before transfection.
Cell medium was replaced with medium supplemented
with 1% charcoal-stripped (CS) FBS lacking phenol red
and serum on the day of transfection, which was per-
formed using the Fugene 6 Reagent as recommended by
the manufacturer (Roche Diagnostics, Milan, Italy) with
a mixture containing 0.5 μg of reporter plasmid, 2 ng of
pRL-TK, 0.1 μg of effector plasmid and 0.1 μg of full
length AR expression plasmid where applicable. After 6
h, the medium was replaced again with serum-free med-
ium lacking phenol red and supplemented with 1% CS-
FBS, treatments were added at this point and cells were
incubated for an additional 18 h. Luciferase activity was
then measured using the Dual Luciferase Kit (Promega,
Milan, Italy) according to the manufacturer’s recom-
mendations. Firefly luciferase activity was normalized to
the internal transfection control provided by the Renilla
luciferase activity. The normalized relative light unit
values obtained from cells treated with vehicle were set
as one-fold induction upon which the activity induced
by treatments was calculated.
For the gene silencing experiments, cells were plated
into 10-cm dishes, maintained in serum-free medium
for 24 h and then transfected for an additional 48 h
before treatments using Fugene 6 (according to the
manufacturer’s recommendations) and control vector
(shRNA) or shGPER.
Ligand binding assays
In ligand binding assay for ERa, the ability of MIBE to
compete with [3H]E2 was evaluated and compared with
that of E2. Two picomoles of purified recombinant
human ERa protein purchased from PanVera,
Invitrogen S.r.l. (Milan, Italy), each in 20 mM HEPES,
pH 7.4, 1.5 mM EDTA, 0.5 mM dithiothreitol, and 10%
(v/v) glycerol, was incubated with 1 nM [2,4,6,7-3H]E2
(89 Ci/mmol; Ge Healthcare, Milan, Italy) and increas-
ing concentrations of nonlabeled E2 or MIBE for two
hours at 37°C in a humidified atmosphere of 95% air/5%
CO2. Bound and free radioligands were separated on
Sephadex G-25 PD-10 columns. The amount of recep-
tor-bound [3H]E2 was determined by liquid scintillation
counting.
In ligand binding assay for GPER, SkBr3 cells were
grown in 10-cm cell culture dishes, washed two times
and incubated with 1 nM [2,4,6,7-3H]E2 (89 Ci/mmol;
Ge Healthcare, Milan, Italy) in the presence or absence
of an increasing concentration of nonlabeled competi-
tors (E2, G-1, OHT and MIBE). Then, cells were incu-
bated for two hours at 37°C and washed three times
with ice-cold PBS; the radioactivity collected by 100%
ethanol extraction was measured by liquid scintillation
counting. Competitor binding was expressed as a per-
centage of maximal specific binding. Each point is the
mean of three observations.
Reverse transcription and real-time PCR
Gene expression was evaluated by real-time PCR as we
previously described [37]. For Cyclin D1, IRS-1, PR, pS2,
c-fos, CTGF, Cyr61, EGR1, and the ribosomal protein
18S, which was used as a control gene to obtain normal-
ized values, the primers were: 5’-GTCTGTGCAT
TTCTGGTTGCA-3’ (Cyclin D1 forward) and 5’-
GCTGGAAACATGCCGGTTA-3’ (Cyclin D1 reverse);
5’-GCCCGTGTTACTGTTCATTCAG-3’ (IRS-1 for-
ward) and 5’-AATAACGGACACTGCACAACAGTCT-
3’ (IRS-1 reverse); 5’-GAGTTGTGAGAGCACTG-
GATGCT-3’ (PR forward) and 5’-CAACTGTAT
GTCTTGACCTGGTGAA-3’ (PR reverse); 5’-GCCCCC
CGTGAAAGAC-3’ (pS2 forward) and 5’-CGTCGAAA-
CAGCAGCCCTTA-3’ (pS2 reverse); 5’-CGAGCCCT
TTGATGACTTCCT-3’ (c-fos forward), 5’-GGAGCGG
GCTGTCTCAGA-3’ (c-fos reverse); 5’-ACCTGTG
GGATGGGCATCT-3’ (CTGF forward), 5’-CAGGC
GGCTCTGCTTCTCTA-3’ (CTGF reverse); 5’-GAGT




and 5’- GGCGTCCCCCAACTTCTTA -3’ (18S forward)
and 5’- GGGCATCACAGACCTGTTATT -3’ (18S
reverse), respectively.
Western blotting
Cells were grown in 10-cm dishes, exposed to ligands,
and then lysed in 500 μL of 50 mmol/L NaCl, 1.5
mmol/L MgCl2, 1 mmol/L EGTA, 10% glycerol, 1%
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Triton X-100, 1% sodium dodecyl sulfate (SDS), and a
mixture of protease inhibitors containing 1 mmol/L
aprotinin, 20 mmol/L phenylmethylsulfonyl fluoride and
200 mmol/L sodium orthovanadate. Protein concentra-
tion was determined using Bradford reagent according
to the manufacturer’s recommendations (Sigma-Aldrich,
Milan, Italy). Equal amounts of whole protein extract
were resolved on a 10% SDS-polyacrylamide gel, trans-
ferred to a nitrocellulose membrane (GE Healthcare,
Milan, Italy), probed overnight at 4°C with antibodies
against Cyclin D1 (M-20), IRS-1 (A-19), c-fos (H-125),
CTGF (L-20), GPER (N-15), pEGFR Tyr 1173 (sc-
12351), b-actin (C-2), phosphorylated ERK1/2 (E-4) and
ERK2 (C-14) (all purchased from Santa Cruz Biotech-
nology, DBA, Milan, Italy), and then revealed using the
ECL™ Western Blotting Analysis System (GE Health-
care, Milan, Italy).
Proliferation assay
For quantitative proliferation assay, cells (1 × 105) were
seeded in 24-well plates in regular growth medium.
Cells were washed once they had attached and then
were incubated in medium containing 2.5% charcoal-
stripped FBS with the indicated treatments; medium was
renewed every two days (with treatments) before count-
ing, using the Countess Automated Cell Counter, as
recommended by the manufacturer’s protocol (Invitro-
gen S.r.l., Milan, Italy).
Statistical analysis
Statistical analysis was done using ANOVA followed by
Newman-Keuls’ testing to determine differences in
means. P < 0.05 was considered as statistically
significant.
Results
Molecular modeling and binding assays demonstrate that
MIBE is a ligand of both ERa and GPER
On the basis of the results obtained in docking simula-
tions as described in the Materials and methods section,
we evaluated the affinity of MIBE for the ligand binding
pockets of both ERa and GPER with respect to E2 and
G-1, respectively (Figure 2). Docking E2 to the hormone
binding pocket of a closed conformation of ERa (Figure
2a), we observed a binding mode similar to that
reported in the experimental crystallographic complex
(superposition of the solution provided by GOLD to the
crystallographic structure led to a RMSD of 0.092Å)
[32]. Docking MIBE to the same pocket using ERa in
both the closed and open conformation, we evidenced a
better affinity for the last conformation (Figure 2b) and
a binding mode similar to that adopted by the ER
antagonist OHT in the crystallographic structure (PDB
code 3ERT) [33].
As it concerns the GPER ligand binding pocket, visual
inspection showed that it lies within a deep cleft in where
10 hydrophobic residues (V116, Met133, Leu137,
Phe206, Phe208, Phe 278, Ile279, Ile308, Val309 and
Phe314) and 5 polar amino acids (Tyr123, Gln138,
Asp210, Glu275 and His282) contribute to stabilize the
ligands through Van der Waals interactions and hydro-
gen bonds, respectively. Using GPER as a target, docking
simulations confirmed a good affinity of the protein for
the agonist G-1 (Figure 2c) as previously demonstrated
both in silico and in vitro [29]. Next, we docked MIBE to
GPER using the same settings and parameters as for G-1.
MIBE, which was positioned within the GPER binding
site (Figure 2d), displayed a high affinity for GPER, even
better than that exhibited by G-1. In particular, MIBE
binds to GPER forming hydrogen bonds with the hydro-
xyl groups located on its branched arms, on one side
with Y123 OH, on the other with Q215 NE2 and H282
ND1 atoms. MIBE is also stabilized in the protein bind-
ing pocket by Van der Waals interactions of its methyl
groups with residues F208, I279, T305 and I308, while a
π-π stacking interaction is formed by the aromatic rings
of F208 and the indole ring of MIBE. Starting from the
aforementioned observations, we performed diverse
assays to fully evaluate the ligand binding properties and
the potential agonist/antagonist activity of MIBE exerted
through ERa and GPER.
In order to confirm whether MIBE is a ligand of ERa,
we performed competitive binding experiments by using
the recombinant ERa protein. MIBE displaced the radi-
olabeled E2 in a dose-dependent manner (Figure 3a)
indubitably demonstrating its capability to bind to ERa
in a direct fashion, although with a lower binding affi-
nity in respect to E2 and OHT as 10 μM MIBE induced
approximately 40% displacement of [3H]E2. On the
basis of the ability of MIBE to interact with GPER in
docking simulations, we also performed ligand binding
studies using radiolabeled E2 as a tracer in ER-negative
but GPER-positive SkBr3 breast cancer cells, as pre-
viously reported [28]. Hence, we performed binding
experiments using cold E2, MIBE, the selective GPER
ligand G-1 and OHT, which has been largely reported
to act as a GPER agonist [7]. Interestingly, MIBE
showed the capability to displace [3H]E2 (Figure 3b) in
accordance with the results obtained in docking simula-
tions. E2, G-1 and OHT confirmed the ability to com-
pete with [3H]E2 as previously shown [28]. Collectively,
our findings demonstrate that MIBE is a ligand of both
ERa and GPER.
MIBE inhibits both ER transactivation and gene
expression induced by E2
On the basis of these results, we aimed to ascertain
whether MIBE could function as an agonist or
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antagonist for ERa and GPER. Initially, we evaluated
the potential of MIBE in activating or inhibiting the
ERa-mediated signaling. Hence, we transiently trans-
fected an ER-reported gene in MCF7 breast cancer
cells, which express ERa but not ERb as judged by
RT-PCR (data not shown). The reporter plasmid used
carries firefly luciferase sequences under the control of
an ERE upstream of the thymidine kinase promoter.
As an internal transfection control, we co-transfected a
plasmid expressing renilla luciferase which is enzymati-
cally distinguishable from firefly luciferase by the
strong cytomegalovirus enhancer/promoter. MIBE did
not show any capability to transactivate ERa; however,
it abrogated the luciferase activity induced by E2 like
the ER antagonist OHT (Figure 4a, b). To confirm
these data and to examine the response of ERb, we
transiently transfected the ER-negative Hek293 cells
with chimeric proteins consisting of the DNA binding
domain (DBD) of the yeast transcription factor Gal4
and the ligand binding domain (LBD) of ERa (GalERa)
or ERb (GalERb), respectively. MIBE did not activate
GalERa and GalERb (Figure 4c, d), but prevented the
transactivation of these chimeric proteins by E2
mimicking the inhibitory activity of OHT (Figure 4e,
f). In order to evaluate whether MIBE acts through a
further member of the steroid receptor superfamily as
the AR, we transiently transfected the ER-negative
Hek293 cells with an AR reporter gene along with the
expression vector encoding AR. DHT transactivated
the AR reporter gene, whereas MIBE neither activated
AR nor prevented the DHT-induced activation of AR
(Additional file 1). Together, these results provide
Figure 2 GPER and ERalpha docking simulations. (a-b) The three-dimensional model of ERalpha is schematically reported as a light blue
ribbon cartoon; residues involved in ligand binding are drawn as sticks. (a) The binding modes of E2 (pink sticks) to ERalpha in the “closed
conformation” is shown. (b) The MIBE moiety (orange sticks) is drawn in its favorable conformation bound to ERalpha (open conformation), with
the helix 12 displaced with respect to the position exhibited in the ERalpha-E2 complex. (c-d) The GPER model is reported as green ribbon and
residues involved in ligand binding are drawn as sticks. (c) G-1 is drawn in yellow. (d) The MIBE moiety is drawn as orange sticks.
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evidence regarding the specific action of MIBE on ER-
mediated signaling.
In order to further demonstrate that MIBE acts as an
ERa antagonist, we evaluated its ability to repress in
MCF7 cells the mRNA expression of well known E2 tar-
get genes like pS2, Cyclin D1, PR and IRS-1. As deter-
mined by real-time PCR, the E2-dependent increase of
all genes examined was prevented by MIBE as obtained
using OHT (Figure 5a). Similarly, the protein expression
of cyclin D1 and IRS-1 induced by E2 in MCF7 cells
was inhibited by MIBE (and OHT) (Figure 5b, c).
MIBE prevents the proliferative effects triggered by E2
Considering that the regulation of estrogen target
genes connects the signaling of E2 with the prolifera-
tion of breast cancer cells [40,41], we wanted to deter-
mine the biological significance of the antagonist
action elicited by MIBE through ERa. MIBE as OHT
did not stimulate growth effects used alone (Figure
5d); however, both compounds abolished the prolifera-
tion of MCF7 cells induced by E2 (Figure 5e). Hence,
MIBE can be considered as an ER antagonist on the
basis of its full inhibitory activity elicited on ER-
mediated signaling.
MIBE prevents the GPER-mediated EGFR and ERK
activation
Having established that MIBE is an inhibitor of ERa, we
aimed to determine its functional activity on the GPER-
mediated transduction pathway. Previous studies have
indicated that GPER activation triggers the EGFR-
dependent signaling in cancer cells, even involving a
functional cross-talk between these receptors [8,9,23].
Then, we sought to evaluate the role played by GPER in
EGFR phosphorylation upon exposure to its cognate
ligand. Notably, in SkBr3 cells the EGFR activation
induced by EGF was prevented by knocking down
GPER expression (Figure 6a-d) as observed in the pre-
sence of MIBE (Figure 6e, f), which further demon-
strated that it acts as an inhibitor of GPER-mediated
function. Accordingly, the activation of EGFR triggered
by G-1 was abolished in the presence of MIBE, hence
confirming its inhibitory activity on GPER-mediated sig-
naling (Additional file 2). Corroborating the aforemen-
tioned findings, MIBE showed the capability to inhibit
the ERK activation upon EGF exposure (Figure 6g, h) as
well as by the GPER activators E2, G-1 and OHT (Fig-
ure 6i-l). Overall, these results suggest that MIBE acting
as an inhibitor of GPER blocks the EGFR activation and
the ERK phosphorylation induced by EGF and the
ligands of GPER, thus preventing the functional cross-
talk between GPER and EGFR.
MIBE inhibits gene transcription and cell proliferation
mediated by GPER
The characterization of the transcriptional response to
GPER signaling has recently identified a set of target
genes that mediate the stimulatory effects triggered by
GPER activation in cancer cells [24]. Hence, we per-
formed real-time PCR experiments to evaluate the
potential of MIBE in regulating the expression of GPER-
dependent genes. Of note, the up-regulation of c-fos,
CTGF, Cyr61 and EGR1 induced by the GPER agonists
E2, G-1 and OHT in SKBr3 cells was abolished in the
presence of MIBE (Figure 7a). In accordance with these
results, MIBE also prevented the increase of both c-fos
and CTGF at the protein level (Figure 7b, c). Next, we
wondered what might be the biological significance of
the inhibitory action of MIBE through GPER signaling.
As shown in panel d of Figure 7, the proliferative effects
elicited by E2, G-1 and OHT in SKBr3 cells were inhib-
ited by MIBE. Altogether, these findings demonstrate
that MIBE acts as an antagonist of both ERa and GPER
in breast cancer cells.
Discussion
In the present study, we identified the first ligand of
ERa and GPER, referred to as MIBE, which acts as an
Figure 3 MIBE is a ligand of GPER and ERalpha. (a) MIBE
competes with [3H]E2 for the binding to ERalpha. Competitive
binding of increasing concentrations of unlabelled E2, OHT and
MIBE to recombinant human ERalpha protein. Each data point
represents the mean ± SD of triplicate samples of three separate
experiments. (b) Ligand binding assay in SkBr3 cells. Competition
curves of increasing concentration of unlabelled E2, G-1, OHT and
MIBE expressed as a percentage of maximum specific [3H]E2
binding. Each data point represents the mean ± SD of three
separate experiments performed in triplicate.
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Figure 4 MIBE inhibits the transactivation of ERalpha induced by E2. (a) MCF7 cells were transfected with the ER luciferase reporter gene
(EREluc) along with the internal transfection control Renilla Luciferase and treated with increasing concentrations (logarithmic scale) of E2, the
ER antagonist OHT and MIBE. (b) MCF7 cells were transfected with the ER reporter gene and the internal transfection control Renilla Luciferase
and treated with 10 nM E2 in combination with increasing concentration of OHT or MIBE, as indicated. (c, e) Hek293 cells were transfected with
Gal4 reporter gene GK1, the Gal4 fusion proteins encoding the Ligand Binding Domain (LBD) of ERa (GalERalpha) or ERbeta (GalERbeta) and the
internal transfection control Renilla Luciferase and treated with increasing concentrations (logarithmic scale) of E2, OHT and MIBE. (d, f) Hek293
cells were transfected with the Gal4 reporter gene GK1, the Gal4 fusion proteins GalERalpha or GalERbeta and the internal transfection control
Renilla Luciferase and treated with 100 nM E2 in combination with increasing concentrations of OHT or MIBE, as indicated. Each data point
represents the mean ± SD of three experiments performed in triplicate.
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antagonist of both receptors in breast cancer cells. By
molecular modeling and binding experiments we
demonstrated that MIBE binds to both receptors,
while through functional assays we showed that MIBE
inhibits the ERa- and GPER-mediated signaling. In
particular, using the ER-positive MCF7 and ER-nega-
tive SkBr3 breast cancer cells as a model system, we
characterized the biological properties of MIBE. We
found that in MCF7 cells MIBE blocks the ER
Figure 5 MIBE inhibits gene expression and proliferation
induced by E2 in MCF7 cells. (a) Evaluation of mRNA expression
of Cyclin D1 (Cyc D1), IRS-1, Progesterone Receptor (PR) and pS2 by
real-time PCR in MCF7 cells. Cells were treated for 24 h with vehicle,
10 nM E2, 1 microM OHT and 10 microM MIBE alone or in
combination, as indicated. Results obtained from experiments
performed in triplicate were normalized for 18S expression and
shown as fold change of RNA expression compared to cells treated
with vehicle. Each data point represents the mean ± SD of three
independent experiments performed in triplicate. (b) Immunoblots
of protein levels of Cyclin D1 (Cyc D1) and IRS-1 from MCF7 cells.
Cells were treated for 24 h with vehicle (-), 10 nM E2, 1 microM
OHT and 10 microM MIBE alone or in combination, as indicated. b-
actin serves as loading control. Data shown are representative of
three independent experiments. (c) Densitometric analysis of three
independent experiments, protein expressions are normalized to
beta-actin. (•), (◦) indicate P < 0.05 for cells receiving vehicle versus
treatments. (d) MCF7 cells were treated for five days with vehicle,
increasing concentrations (logarithmic scale) of E2, OHT and MIBE
and counted on Day 6. (e) Cells were treated for five days with
vehicle (-), 10 nM E2, 1 microM OHT and 10 microM MIBE alone or
in combination, as indicated, and then the proliferation was
evaluated by cell counts on Day 6. The proliferation of cells
receiving vehicle was set as 100% upon which cell growth induced
by treatments was calculated. Each data point is the average ± SD
of three independent experiments performed in triplicate. (•)
indicates P < 0.05 for cells receiving vehicle (-) versus treatments.
Figure 6 MIBE prevents the phosphorylation of EGFR and
ERK1/2. (a) EGFRTyr1173 phosphorylation after treatment (five
minutes) with vehicle (-) and 100 ng/ml EGF in SkBr3 cells
transfected with shRNA or shGPER. (b) Densitometric analysis of
three independent experiments, EGFRTyr1173 expressions are
normalized to EGFR. (c) Efficacy of GPER silencing obtained using
shGPER. (d) Densitometric analysis of three independent
experiments. GPER expressions are normalized to beta-actin. (e)
EGFRTyr1173 phosphorylation after treatment (five minutes) with
vehicle (-) and 100 ng/ml EGF alone and in combination with 10
μM MIBE. (f) Densitometric analysis of three independent
experiments. EGFRTyr1173 expressions are normalized to EGFR. (g)
ERK1/2 activation in SkBr3 cells treated for five minutes with vehicle
(-) or 100 ng/ml EGF alone and in combination with 10 microM
MIBE. (h) Densitometric analysis of three independent experiments.
ERK1/2 expressions are normalized to ERK2. (i) ERK1/2 activation in
SkBr3 cells treated for 15 minutes with vehicle (-), 100 nM E2, 1
microM G-1 and 5 microM OHT alone and in combination with 10
microM MIBE. Data shown are representative of three independent
experiments. (i) Densitometric analysis of three independent
experiments. ERK1/2 expressions are normalized to ERK2. (•)
indicates P < 0.05 for cells receiving vehicle versus treatments.
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transactivation induced by E2 as well as the ER-
mediated gene regulation and cell proliferation. In
addition, in SkBr3 cells MIBE prevented the GPER-
dependent responses, such as rapid ERK phosphoryla-
tion, gene transcription and growth effects induced by
the GPER agonists E2, OHT and G-1. The exclusive
antagonistic action exerted by MIBE on both ERa and
GPER could represent a novel promising tool for a
more comprehensive pharmacological approach in
estrogen-dependent tumors like breast cancer, which
express one or both receptors from the onset or fol-
lowing tumor progression.
Breast cancer is the most commonly diagnosed inva-
sive malignancy and the second leading cause of cancer
death in women [42]. Endocrine treatment along with
surgery, chemotherapy, radiotherapy and targeted ther-
apy are fundamental modalities for the therapeutic man-
agement of breast cancer. The expression of ERa in
breast carcinomas correlates with the beneficial response
to anti-estrogens [43], whereas the lacking of ERa is
coupled to a worse prognosis and to short disease-free
survival rates [44]. On the basis of the main role exerted
by ERa in the development and progression of breast
cancer and considering that this receptor is expressed in
approximately 70% of breast tumors, the ER antagonist
tamoxifen has been widely used, although its effective-
ness is limited by de novo and acquired resistance [45].
In accordance with these data, comparative clinical stu-
dies have indicated that aromatase inhibitors blocking
estrogen biosynthesis may provide major benefits in
respect to ERa antagonists in breast cancer patients
[46]. Among the various mechanisms involved in the
resistance to endocrine treatment, the activation of
transduction pathways different from those mediated by
ERa has been proposed. For instance, an increased
expression and/or activation of growth factor receptors,
such as EGFR/HER2, have been associated with the fail-
ure of endocrine therapy in breast tumors [47]. More-
over, the existence of alternative ERs able to mediate
estrogen signaling without exhibiting any sensitivity to
the repressive action of the ER antagonists could be also
involved in the resistance to endocrine agents. In this
scenario, it has been recently demonstrated that GPER
acts as an additional receptor mediating the effects of
estrogens in a wide number of cell types, such as breast,
endometrial and ovarian cancer cells [7]. Of note,
diverse studies have shown that E2 as well as the anti-
estrogens tamoxifen and ICI bind to and activate GPER
signaling, including ERK phosphorylation and gene tran-
scription, which in turn lead to cancer cell proliferation
and migration [7].
The activation of the GPER transduction pathway
requires the EGFR transactivation [8], in accordance
with evidence showing that the agonist stimulation of
diverse G-protein coupled receptors (GPCRs) triggers
the transactivation of EGFR through the release of EGF-
like ligands tethered at the cell surface and the subse-
quent generation of intracellular signaling [48]. In addi-
tion, the functional crosstalk which occurs between
members of GPCR and growth factor receptor families
contributes to the progression of different tumors [8,48].
In this regard, we have previously reported that GPER
and EGFR physically and functionally interact in both
ER-negative and ER-positive cancer cells [22,23].
Recently, it has also been found that a crosstalk among
EGFR, the nerve growth factor (NGF) receptor TrkA
Figure 7 MIBE inhibits GPER target genes and proliferation
induced by E2, G-1 and OHT. (a) The expression of c-fos, CTGF,
Cyr61 and EGR1 induced in SkBr3 cells by 1 h treatment with 100
nM E2, 1 microM G-1 and 5 microM OHT is inhibited in presence of
10 microM MIBE, as evaluated by real-time PCR. Results obtained
from experiments performed in triplicate were normalized for 18S
expression and shown as fold change of RNA expression compared
to cells treated with vehicle. Each data point represents the mean ±
SD of three independent experiments performed in triplicate. (b)
The up-regulation of c-fos and CTGF protein levels induced in SkBr3
cells by 2 h treatment with 100 nM E2, 1 microM G-1 and 5 microM
OHT were abolished in presence of 10 microM MIBE. Data shown
are representative of three independent experiments. beta-actin
serves as a loading control. (c) Densitometric analysis of c-fos and
CTGF protein expressions normalized to beta-actin. (•), (◦) indicate P
< 0.05 for cells receiving vehicle versus treatments. (d) The
proliferation of SkBr3 cells upon treatment with 100 nM E2, 100 nM
G-1 and 100 nM OHT was inhibited by 1 microM MIBE, as indicated.
Cells were treated for five days with the indicated treatments and
counted on Day 6. Proliferation of cells receiving vehicle was set as
100% upon which cell growth induced by treatments was
calculated. Each data point is the average ± SD of three
independent experiments performed in triplicate. (•), (◦), (▪), indicate
P < 0.05 for cells receiving vehicle (-) versus treatments.
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and the GPCR Formyl Peptide Receptor (FPR) occurs in
monocytes [49]. In particular, the inhibition of EGFR
prevented the ligand-dependent responses mediated by
the other two receptors, while the inhibition of FPR
abolished the EGFR and TrkA phosphorylation induced
by EGF and NGF, respectively. Accordingly, the silen-
cing of each receptor suppressed the capability of the
other receptors to mediate the ligand-induced actions
like ERK phosphorylation [49]. In line with these find-
ings, our current results provide novel insight into the
functional crosstalk between GPER and EGFR in cancer
cells. Notably, we show for the first time that the activa-
tion of EGFR induced by its cognate ligand EGF is abol-
ished by knocking down GPER expression or in the
presence of MIBE, which is an inhibitor of GPER as
ascertained in the present study. Nevertheless, further
studies are needed to better understand the role played
by GPER in the activation of EGFR by its cognate ligand
EGF and to appreciate the potential of MIBE in prevent-
ing the crosstalk between GPER and EGFR which was
previously well described [23].
On the basis of these remarks, it remains to be evalu-
ated that the potential of MIBE to interfere with the
functional crosstalk between EGFR and ERa, toward a
better characterization of its inhibitory activity elicited
in cell contexts expressing both receptors. In particular,
considering that a physical and functional interaction
between EGFR and ER leads to the activation of multi-
ple intracellular cascades, including MAPK, phosphoino-
sitide 3-kinase (PI3K) and other protein kinases [50-53],
it would be interesting to ascertain whether MIBE could
alter these transduction signals that have been involved
in the proliferation of cancer cells [50,54-58].
In 2005, two reports provided evidence on the capabil-
ity of estrogens and anti-estrogens to bind to GPER
[10,19]. In particular, the ER antagonists tamoxifen and
ICI displayed a high binding affinity for GPER, as
assessed in competition assays. Surprisingly, unlike the
antagonistic properties exhibited by these agents on the
classical ER-mediated pathways, both tamoxifen and ICI
act as GPER agonists [8,9,19]. In the following years,
further ER ligands and activators showed the ability to
bind to GPER eliciting promiscuous actions through the
two receptors. For instance, the phytoestrogen genistein
and the xenoestrogen bisphenol A, which exert estro-
gen-like activities binding to and activating ERa [9,59],
displayed the ability to bind to and activate GPER sig-
naling [9,27,60]. As it concerns the pesticide atrazine, it
exerted estrogenic effects without binding to ERs [61]
and exhibiting the capability to activate the GPER-
mediated pathway despite a low binding affinity for this
receptor [25,27]. Unlike E2 which exhibited ERa and
GPER agonism in several investigations [7], the well
known ERa ligand and activator estriol showed antago-
nistic properties for GPER-mediated signaling [28].
Besides, G-1 [29] and G-15, along with its derivatives
[30,31] as ligands activated or inhibited, respectively, the
GPER-mediated signaling, while some GPER antagonists
triggered at high concentrations ER-dependent tran-
scriptional responses [30].
GPER expression was indicated as a potential predic-
tor of biological aggressive features in breast carcinomas
[16]. Although a significant association between ERa
and GPER was observed, approximately 50% of ERa-
negative breast tumors retained GPER suggesting that
the expression of these receptors may not be interde-
pendent [16]. On the basis of these and the aforemen-
tioned findings, tumor cells that express GPER but lack
ERa may be stimulated by estrogens and even by anti-
estrogens, such as tamoxifen. In this regard, it should be
noted that the stimulatory effects on cancer progression
elicited by estrogens via both ERa and GPER and by
ERa antagonists through GPER address the need to dis-
cover novel drugs targeting simultaneously both recep-
tors, in order to obtain major therapeutic benefits in
respect to the use of the current selective antagonists.
Conclusions
The exclusive antagonistic activity exerted by MIBE on
ERa- and GPER-mediated signaling as shown in the
present study (Figure 8), could represent a promising
pharmacological approach either at the beginning or
during the progression of breast tumors which express
one or both receptors. In this respect, further studies
are needed to examine whether MIBE could be consid-
ered a useful tool towards a more comprehensive treat-
ment in breast cancer.
Figure 8 Schematic representation of the inhibitory activity
exerted by MIBE on GPER- and ER-mediated signaling.
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Additional material
Additional file 1: MIBE does not activate AR. Hek293 cells were
transfected with AR luciferase reporter gene (ARE-luc) and AR expression
plasmid along with the internal transfection control Renilla Luciferase,
and treated with 10 nM DHT alone and in combination with 10 μM
MIBE, as indicated. The normalized luciferase activities of cells treated
with vehicle (-) were set as one-fold induction, upon which the activities
induced by treatments were calculated. Each data point represents the
mean ± SD of three experiments performed in triplicate.
Additional file 2: MIBE prevents the phosphorylation of EGFR
induced by G-1. (a) EGFRTyr1173 phosphorylation after treatment (30
minutes) with vehicle (-) and 1 μM G-1 alone and in combination with
10 μM MIBE. (b) Densitometric analysis of three independent
experiments, EGFRTyr1173 expressions are normalized to EGFR.
Abbreviations
AR: androgen receptor; CAFs: cancer associated fibroblasts; CS: charcoal-
stripped; DBD: DNA binding domain; DHT: 5α-dihydrotestosterone; DMSO:
dimethyl sulfoxide; E2: 17β-estradiol; EGFR: epidermal growth factor receptor;
ER: estrogen receptor; ERK: extracellular signal-regulated kinase; FPR: formyl
peptide receptor; G-1: 1-[4-(6-bromobenzo[1:3]dioxol-5-yl)-3a:4:5:9b-
tetrahydro-3H-cyclopenta[c]quinolin-8-yl]-ethanone; G-15: 4-(6-Bromobenzo
[1:3]dioxol-5-yl)-3a:4:5:9b-tetrahydro-3H-cyclopenta[c]quinoline; GPCRs: G-
protein coupled receptors; GPER: G protein-coupled estrogen receptor; HB-
EGF: heparan-bound epidermal growth factor; LBD: ligand binding domain;
MAPK: mitogen-activated protein kinase; MIBE: ethyl 3-[5-(2-ethoxycarbonyl-
1-methylvinyloxy)-1-methyl-1H-indol-3-yl]but-2-enoate; NGF: nerve growth
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phospholipase C; SDS: sodium dodecyl sulfate; TLC: thin layer
chromatography.
Acknowledgements
This work was supported by Associazione Italiana per la Ricerca sul Cancro
(AIRC, project n. 8925/2009 and project Calabria 2011), Fondazione Cassa di
risparmio di Calabria e Lucania and Ministero dell’Istruzione, dell’Università e
della Ricerca (MIUR) (project PRIN 2008PK2WCW/2008).
Author details
1Dipartimento Farmaco-Biologico, Università della Calabria, via Bucci, 87036
Rende, Italy. 2Dipartimento di Scienze Farmaceutiche, Università della
Calabria, via Bucci, 87036 Rende, Italy. 3U.O.S. Biopolimeri e Proteomica,
Azienda Ospedaliera Universitaria IRCCS San Martino IST - Istituto Nazionale
per la Ricerca sul Cancro, Largo Benzi 10, 16132 Genova, Italy.
Authors’ contributions
RL designed and performed the experiments, and wrote the paper. MFS and
MP performed the experiments. MSS and AC synthesized MIBE. CR
performed docking simulations. MM analyzed data and wrote the paper. All
authors read and approved the final manuscript for publication.
Competing interests
The authors declare that they have no competing interests.
Received: 30 September 2011 Revised: 18 December 2011
Accepted: 17 January 2012 Published: 17 January 2012
References
1. Deroo BJ, Korach KS: Estrogen receptors and human disease. J Clin Invest
2006, 116:561-570.
2. Ascenzi P, Bocedi A, Marino M: Structure-function relationship of estrogen
receptor alpha and beta: impact on human health. Mol Aspects Med 2006,
27:299-402.
3. Dupont WD, Page DL: Menopausal estrogen replacement therapy and
breast cancer. Arch Intern Med 1991, 151:67-72.
4. Scott JA, McGuire WL: New molecular markers of prognosis in breast
cancer. In Endocrine-Dependent Tumors. Edited by: Voigt K-D, Knabbe C.
New York: Raven Press; 1991:179-196.
5. Ponzone R, Biglia N, Jacomuzzi ME, Mariani L, Dominguez A, Sismondi P:
Antihormones in prevention and treatment of breast cancer. Ann NY
Acad Sci 2006, 1089:143-158.
6. Herynk MH, Fuqua SA: Estrogen receptors in resistance to hormone
therapy. Adv Exp Med Biol 2007, 608:130-143.
7. Maggiolini M, Picard D: The unfolding stories of GPR30, a new membrane
bound estrogen receptor. J Endocrinol 2010, 204:105-114.
8. Filardo EJ, Quinn JA, Bland KI, Frackelton AR Jr: Estrogen-induced
activation of Erk-1 and Erk-2 requires the G protein-coupled receptor
homolog, GPR30, and occurs via trans-activation of the epidermal
growth factor receptor through release of HB-EGF. Mol Endocrinol 2000,
14:1649-1660.
9. Maggiolini M, Vivacqua A, Fasanella G, Recchia AG, Sisci D, Pezzi V,
Montanaro D, Musti AM, Picard D, Andò S: The G protein-coupled
receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and
phytoestrogens in breast cancer cells. J Biol Chem 2004, 279:27008-27016.
10. Thomas P, Pang Y, Filardo EJ, Dong J: Identity of an estrogen membrane
receptor coupled to a G protein in human breast cancer cells.
Endocrinology 2005, 146:624-632.
11. Vivacqua A, Bonofiglio D, Recchia AG, Musti AM, Picard D, Andò S,
Maggiolini M: The G protein-coupled receptor GPR30 mediates the
proliferative effects induced by 17β-estradiol and hydroxytamoxifen in
endometrial cancer cells. Mol Endocrinol 2006, 20:631-646.
12. Albanito L, Madeo A, Lappano R, Vivacqua A, Rago V, Carpino A, Oprea TI,
Prossnitz ER, Musti AM, Andò S, Maggiolini M: G protein-coupled receptor
30 (GPR30) mediates gene expression changes and growth response to
17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells.
Cancer Res 2007, 67:1859-1866.
13. Vivacqua A, Bonofiglio D, Albanito L, Madeo A, Rago V, Carpino A,
Musti AM, Picard D, Andò S, Maggiolini M: 17β-Estradiol, genistein, and 4-
hydroxytamoxifen induce the proliferation of thyroid cancer cells
through the G protein coupled-receptor GPR30. Mol Pharmacol 2006,
70:1414-1423.
14. Chan QK, Lam HM, Ng CF, Lee AY, Chan ES, Ng HK, Ho SM, Lau KM:
Activation of GPR30 inhibits the growth of prostate cancer cells through
sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of
p21, and induction of G(2) cell-cycle arrest. Cell Death Differ 2010,
17:1511-1523.
15. Chevalier N, Bouskine A, Fenichel P: Role of GPER/GPR30 in tumoral
testicular germ cells proliferation. Cancer Biol Ther 2011, 12:2-3.
16. Filardo EJ, Graeber CT, Quinn JA, Resnick MB, Giri D, DeLellis RA,
Steinhoff MM, Sabo E: Distribution of GPR30, a seven membrane-
spanning estrogen receptor in primary breast cancer and its association
with clinicopathologic determinants of tumor progression. Clin Cancer
Res 2006, 12:6359-6366.
17. Smith HO, Leslie KK, Singh M, Qualls CR, Revankar CM, Joste NE,
Prossnitz ER: GPR30: a novel indicator of poor survival for endometrial
carcinoma. Am J Obstet Gynecol 2007, 196:386.e1-9, discussion 386.e9-e11.
18. Smith HO, Arias-Pulido H, Kuo DY, Howard T, Qualls CR, Lee SJ,
Verschraegen CF, Hathaway HJ, Joste NE, Prossnitz ER: GPR30 predicts poor
survival for ovarian cancer. Gynecol Oncol 2009, 114:465-471.
19. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER: A
transmembrane intracellular estrogen receptor mediates rapid cell
signaling. Science 2005, 307:1625-1630.
20. Prossnitz ER, Maggiolini M: Mechanisms of estrogen signaling and gene
expression via GPR30. Mol Cell Endocrinol 2009, 308:32-38.
21. Quinn JA, Graeber CT, Frackelton AR Jr, Kim M, Schwarzbauer JE, Filardo EJ:
Coordinate regulation of estrogen-mediated fibronectin matrix assembly
and epidermal growth factor receptor transactivation by the G protein-
coupled receptor, GPR30. Mol Endocrinol 2009, 23:1052-1064.
22. Albanito L, Sisci D, Aquila S, Brunelli E, Vivacqua A, Madeo A, Lappano R,
Pandey DP, Picard D, Mauro L, Andò S, Maggiolini M: Epidermal growth
factor induces G protein-coupled receptor 30 expression in estrogen
receptor-negative breast cancer cells. Endocrinology 2008, 149:3799-3808.
23. Vivacqua A, Lappano R, De Marco P, Sisci D, Aquila S, De Amicis F,
Fuqua SA, Andò S, Maggiolini M: G protein-coupled receptor 30
expression is up-regulated by EGF and TGF alpha in estrogen receptor
alpha-positive cancer cells. Mol Endocrinol 2009, 23:1815-1826.
24. Pandey DP, Lappano R, Albanito L, Madeo A, Maggiolini M, Picard D:
Estrogenic GPR30 signalling induces proliferation and migration of
breast cancer cells through CTGF. EMBO J 2009, 28:523-532.
Lappano et al. Breast Cancer Research 2012, 14:R12
http://breast-cancer-research.com/content/14/1/R12
Page 12 of 13
25. Albanito L, Lappano R, Madeo A, Chimento A, Prossnitz ER, Cappello AR,
Dolce V, Abonante S, Pezzi V, Maggiolini M: G-protein-coupled receptor 30
and estrogen receptor-alpha are involved in the proliferative effects
induced by atrazine in ovarian cancer cells. Environ Health Perspect 2008,
116:1648-1655.
26. Madeo A, Maggiolini M: Nuclear alternate estrogen receptor GPR30
mediates 17beta-estradiol-induced gene expression and migration in
breast cancer-associated fibroblasts. Cancer Res 2010, 70:6036-6046.
27. Thomas P, Dong J: Binding and activation of the seven-transmembrane
estrogen receptor GPR30 by environmental estrogens: a potential novel
mechanism of endocrine disruption. J Steroid Biochem Mol Biol 2006,
102:175-179.
28. Lappano R, Rosano C, De Marco P, De Francesco EM, Pezzi V, Maggiolini M:
Estriol acts as a GPR30 antagonist in estrogen receptor-negative breast
cancer cells. Mol Cell Endocrinol 2010, 320:162-170.
29. Bologa CG, Revankar CM, Young SM, Edwards BS, Arterburn JB, Kiselyov AS,
Parker MA, Tkachenko SE, Savchuck NP, Sklar LA, Oprea TI, Prossnitz ER:
Virtual and biomolecular screening converge on a selective agonist for
GPR30. Nat Chem Biol 2006, 2:207-212.
30. Dennis MK, Field AS, Burai R, Ramesh C, Petrie WK, Bologa CG, Oprea TI,
Yamaguchi Y, Hayashi SI, Sklar LA, Hathaway HJ, Arterburn JB, Prossnitz ER:
Identification of a GPER/GPR30 antagonist with improved estrogen
receptor counterselectivity. J Steroid Biochem Mol Biol 2011, 127:358-366.
31. Ramesh C, Nayak TK, Burai R, Dennis MK, Hathaway HJ, Sklar LA,
Prossnitz ER, Arterburn JB: Synthesis and characterization of iodinated
tetrahydroquinolines targeting the G protein-coupled estrogen receptor
GPR30. J Med Chem 2010, 53:1004-1014.
32. Eiler S, Gangloff M, Duclaud S, Moras D, Ruff M: Overexpression,
purification, and crystal structure of native ERα LBD. Protein Expr Purif
2001, 22:165-173.
33. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL:
The structural basis of estrogen receptor/coactivator recognition and
the antagonism of this interaction by tamoxifen. Cell 1998, 95:927-937.
34. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC,
Ferrin TE: UCSF Chimera–a visualization system for exploratory research
and analysis. J Comput Chem 2004, 25:1605-1612.
35. Potdar MK, Mohile SS, Salunkhe MM: Coumarin syntheses via Pechmann
condensation in Lewis acidic chloroaluminate ionic liquid. Tetrahedron
Lett 2001, 42:9285-9287.
36. Subhas Bose D, Rudradas AP, Hari Babu M: The indium(III)
chloridecatalyzed von Pechmann reaction: a simple and effective
procedure for the synthesis of 4-substituted coumarins. Tetrahedron Lett
2002, 43:9195-9197.
37. Lappano R, Recchia AG, De Francesco EM, Angelone T, Cerra MC, Picard D,
Maggiolini M: The cholesterol metabolite 25-hydroxycholesterol activates
estrogen receptor α-mediated signaling in cancer cells and in
cardiomyocytes. PLoS One 2011, 6:e16631.
38. Maggiolini M, Recchia AG, Carpino A, Vivacqua A, Fasanella G, Rago V,
Pezzi V, Briand PA, Picard D, Andò S: Oestrogen receptor beta is required
for androgen-stimulated proliferation of LNCaP prostate cancer cells. J
Mol Endocrinol 2004, 32:777-791.
39. Lanzino M, Sisci D, Morelli C, Garofalo C, Catalano S, Casaburi I, Capparelli C,
Giordano C, Giordano F, Maggiolini M, Andò S: Inhibition of cyclin D1
expression by androgen receptor in breast cancer cells–identification of
a novel androgen response element. Nucleic Acids Res 2010, 38:5351-5365.
40. Altucci L, Addeo R, Cicatiello L, Dauvois S, Parker MG, Truss M, Beato M,
Sica V, Bresciani F, Weisz A: 17β-Estradiol induces cyclin D1 gene
transcription, p36D1-p34cdk4 complex activation and p105Rb
phosphorylation during mitogenic stimulation of G(1)-arrested human
breast cancer cells. Oncogene 1996, 12:2315-2324.
41. Morelli C, Garofalo C, Bartucci M, Surmacz E: Estrogen receptor-alpha
regulates the degradation of insulin receptor substrates 1 and 2 in
breast cancer cells. Oncogene 2003, 22:4007-4016.
42. Coughlin SS, Ekwueme DU: Breast cancer as a global health concern.
Cancer Epidemiol 2009, 33:315-318.
43. Gaskell DJ, Hawkins RA, Sangsterl K, Chetty U, Forrest APM: Relation
between immunocytochemical estimation of oestrogen receptor in
elderly patients with primary breast cancer and response to tamoxifen.
Lancet 1989, 1:1044-1046.
44. Mason BH, Holdaway TM, Mullins PR, Yee LH, Kay RG: Progesterone and
estrogen receptors as prognostic variables in breast cancer. Cancer Res
1983, 43:2985-2990.
45. Osborne CK, Schiff R: Mechanisms of endocrine resistance in breast
cancer. Annu Rev Med 2011, 62:233-247.
46. Rugo HS: The breast cancer continuum in hormone-receptor-positive
breast cancer in postmenopausal women: evolving management
options focusing on aromatase inhibitors. Ann Oncol 2008, 19:16-27.
47. Kurebayashi J: Resistance to endocrine therapy in breast cancer. Cancer
Chemother Pharmacol 2005, 56:39-46.
48. Lappano R, Maggiolini M: G protein-coupled receptors: novel targets for
drug discovery in cancer. Nat Rev Drug Discov 2011, 10:47-60.
49. El Zein N, D’Hondt S, Sariban E: Crosstalks between the receptors tyrosine
kinase EGFR and TrkA and the GPCR, FPR, in human monocytes are
essential for receptors-mediated cell activation. Cell Signal 2010,
22:1437-1447.
50. Migliaccio A, Di Domenico M, Castoria G, de Falco A, Bontempo P, Nola E,
Auricchio F: Tyrosine kinase/p21ras/MAP-kinase pathway activation by
estradiol-receptor complex in MCF-7 cells. EMBO J 1996, 15:1292-1300.
51. Castoria G, Migliaccio A, Bilancio A, Di Domenico M, de Falco A,
Lombardi M, Fiorentino R, Varricchio L, Barone MV, Auricchio F: PI3-kinase
in concert with Src promotes the S-phase entry of oestradiol-stimulated
MCF-7 cells. EMBO J 2001, 20:6050-6059.
52. Castoria G, Migliaccio A, Di Domenico M, Lombardi M, de Falco A,
Varricchio L, Bilancio A, Barone MV, Auricchio F: Role of atypical protein
kinase C in estradiol-triggered G1/S progression of MCF-7 cells. Mol Cell
Biol 2004, 24:7643-7653.
53. Migliaccio A, Di Domenico M, Castoria G, Nanayakkara M, Lombardi M, de
Falco A, Bilancio A, Varricchio L, Ciociola A, Auricchio F: Steroid receptor
regulation of epidermal growth factor signaling through Src in breast
and prostate cancer cells: steroid antagonist action. Cancer Res 2005,
65:10585-10593.
54. Levin ER: Bidirectional signaling between the estrogen receptor and the
epidermal growth factor receptor. Mol Endocrinol 2003, 17:309-317.
55. Migliaccio A, Castoria G, Di Domenico M, Ciociola A, Lombardi M, De
Falco A, Nanayakkara M, Bottero D, De Stasio R, Varricchio L, Auricchio F:
Crosstalk between EGFR and extranuclear steroid receptors. Ann N Y
Acad Sci 2006, 1089:194-200.
56. Migliaccio A, Castoria G, Auricchio F: Src-dependent signalling pathway
regulation by sex-steroid hormones: therapeutic implications. Int J
Biochem Cell Biol 2007, 39:1343-1348.
57. Auricchio F, Migliaccio A, Castoria G: Sex-steroid hormones and EGF
signaling in breast and prostate cancer cells: targeting the association of
Src with steroid receptors. Steroids 2008, 73:880-884.
58. Levin ER: Plasma membrane estrogen receptors. Trends Endocrinol Metab
2009, 20:477-482.
59. Wetherill YB, Akingbemi BT, Kanno J, McLachlan JA, Nadal A,
Sonnenschein C, Watson CS, Zoeller RT, Belcher SM: In vitro molecular
mechanisms of bisphenol A action. Reprod Toxicol 2007, 24:178-198.
60. Dong S, Terasaka S, Kiyama R: Bisphenol A induces a rapid activation of
Erk1/2 through GPR30 in human breast cancer cells. Environ Pollut 2011,
159:212-218.
61. Tennant MK, Hill DS, Eldridge JC, Wetzel LT, Breckenridge CB, Stevens JT:
Chloro-s-triazine antagonism of estrogen action: limited interaction with
estrogen receptor binding. J Toxicol Environ Health 1994, 43:197-211.
doi:10.1186/bcr3096
Cite this article as: Lappano et al.: MIBE acts as antagonist ligand of
both estrogen receptor a and GPER in breast cancer cells. Breast Cancer
Research 2012 14:R12.
Lappano et al. Breast Cancer Research 2012, 14:R12
http://breast-cancer-research.com/content/14/1/R12
Page 13 of 13
